|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the impact of the updated ASCO/CAP guidelines on 1044 FISH tested tumors by comparing categorization according to the 2007, 2013, and 2018 ISH classification criteria.
|
31375912 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Misclassification of HER2 status was observed not only in breast cancers with ASCO-CAP equivocal status but also in breast cancers with an average of fewer than 4.0 HER2 copies per tumor cell when using alternative control probes.
|
30520947 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reflex testing with an alternative chromosome 17 probe using the 2013 ASCO/CAP guidelines reclassified 28.1% of tumor samples that had CEP17 CNA, converting nearly one-half from equivocal to amplified.
|
28192599 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Haematoxylin and eosin (H&E) and IHC slides were reviewed to confirm tumour type, grade and IHC score based on ASCO/CAP 2013 guidelines and their recent revisions.
|
28032917 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Similar to the original patient tumors, they both exhibited faint expression (+) of PLAP, no expression (-) of β-HCG and strong (+++) expression of KIT.
|
26956263 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 2013 CAP/ASCO guideline recommendations for HER2 FISH testing by dual probe assay increased the HER2 amplified and HER2 equivocal tumors.
|
27180259 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A combination of novel PLAP promoter and antibody based specificities has the potential for being developed as a possible therapeutic strategy for PLAP positive neoplasia.
|
26242403 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proximity of UGT with the tumors as well as the immunostaining patterns (PLAP+, OCT3/4+, and CD117/KIT+) suggests that germ cells found in UGT are a risk factor for gonadal tumors.
|
21692598 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven of 14 borderline tumors demonstrated P-LAP immunoreactivity, while 5 of 14 borderline tumors demonstrated GLUT4 immunoreactivity.
|
15907336 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we used polymerase chain reaction (PCR) assays targeted to the AAV-2 rep and cap genes to test tissue specimens from women in an epidemiological study of cervical neoplasia in Jamaica.
|
10440809 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Placental-like alkaline phosphatase (PLAP) is of particular interest because it is frequently present in tumors, where it serves as a marker of malignant transformation.
|
1596896 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At present, the measurement of PLAP has its greatest utility as a tumor marker in seminoma and ovarian cancer.
|
3325192 |
1987 |